Leukemia
Gilteritinib / Xospata (Everest)
Original price was: £412.00.£396.00Current price is: £396.00.Gilteritinib (Brand name: Xospata) is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor approved for the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations.
It is also being actively studied in multiple clinical trials for additional AML subtypes and combination treatment strategies, including first-line therapy, maintenance therapy, and use in combination with chemotherapy or other targeted therapies.
MedFind provides overseas sourcing services for Gilteritinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Ibrutinib (also translated as Yilutini; brand name: Yike; Incepta).
Original price was: £399.00.£238.00Current price is: £238.00.Ibrutinib produced by Incepta (generic name: Ibrutinib, also translated as Yilutini; brand names: Imbruvica, Yike) is an oral Bruton’s tyrosine kinase (BTK) inhibitor. It exerts its antitumor effect by inhibiting BTK, which is required for tumor cell proliferation and metastasis.
It is used for the treatment of relapsed mantle cell lymphoma, relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia.
Ibrutinib / Ibrutinib Capsules / Imbruvica (Everest)
Original price was: £300.00.£249.00Current price is: £249.00.Ibrutinib (Brand name: Imbruvica) is an oral BTK inhibitor used for the treatment of relapsed mantle cell lymphoma (MCL), relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia (WM).
MedFind provides overseas sourcing services for Ibrutinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Ponatinib (Everest)
Price range: £174.00 through £312.00Ponatinib (Brand name: ICLUSIG) is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI) used for the treatment of chronic myeloid leukemia (CML) with the ABL T315I mutation and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
It is also indicated for patients with CML or ALL who are resistant to or intolerant of previous tyrosine kinase inhibitor therapies.
MedFind provides overseas sourcing services for Ponatinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Venetoclax / Venclexta (Everest)
Original price was: £300.00.£256.00Current price is: £256.00.Venetoclax (also known as Venetoclax; Brand name: Venclexta) is the first selective targeted therapy designed to inhibit the B-cell lymphoma-2 (BCL-2) protein, helping promote apoptosis in cancer cells and suppress tumor survival.
MedFind provides overseas sourcing services for Venetoclax through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.